Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Addex Therapeutics Ltd

ADXN ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$3.13

▼ -0.63%

Market Cap $6.00M · Vol 4.23K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$6.00M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

44.16

Momentum

Beta

1.53

vs Market

52W High

$11.80

73.31% below

52W Low

$2.69

17.10% above

Volume

4.23K

Avg 7.98K

P/B

1.26

Price-to-book

ROE

N/A

Return on equity

Free Float

100.00%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Addex Therapeutics Ltd (ADXN) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ADXN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+13.41%

-14.25%

-49.60%

-48.26%

YTD

-59.35%

-64.67%

-63.25%

-98.25%

Financials & Valuation

TTM · Annual

Total Revenue	$218.18K
Net Income	$-8,636,362.00
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-8,839.26%
Net Profit Margin	-21,489.19%
ROE	N/A
ROA · ROIC	-80.30% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	180.22
P/B	1.26
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	218.65M

Technical Indicators

50-Day SMA	$4.22
200-Day SMA	$6.18
RSI (14)	44.16
Beta	1.53
52-Week High	$11.80
52-Week Low	$2.69

Volume Today	4.23K
Avg Daily Volume (30D)	7.98K
Relative Volume	0.53x
Volatility (10D)	123.48
Volatility (30D)	90.55
Free Float	100.00%

Analyst Consensus

N/A

Current Price $3.13

Mean Target N/A

52W Low$2.69 52W High$11.80

Current

Target

$2.69 $11.80

Current Analyst target

· 0 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00R48SV18

ISINUS00654J2069

CountrySwitzerland

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +0.17% ONC BeOne Medicines AG +0.34% 068270.KS Celltrion, Inc. +0.60% MEDP Medpace Holdings, Inc. +0.22% ABVX Abivax SA -1.37%

Company Profile

Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.